- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946445
Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde Cholangiopancreatography (ERCP).
ERCP is a fluoroscopy procedures are associated with significant radiation exposure to patients. Radiation exposure is associated with adverse effects both short term and long term which might negatively impact the quality of life of the patient. The effects of radiation maybe deterministic or stochastic the effects may range from mild such as skin irritation to long term effects such as cancer. Hence there is a need to limit the dosage of radiation exposed to the patient. Therefore, there is a need to establish standard reference levels. Radiation is measured in Dose Area Product (DAP), Effective dose (ED), Reference air Kerma (Ka,r). The radiation exposure is measured for the patients undergoing ERCP from January 2023 to Dec 2025 will be collected. DRLs will be calculated for these metrics. DRL is 3rd quartile of the measured values. The dosage of radiation which the patient receives depends on several factors such as patients BMI, position, complexity of the procedure and several other factors. As a secondary objective several factors affecting the radiation exposure is also noted.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Settipally Vinay kumar, M.D
- Phone Number: 91 9848883993
- Email: settipallyvsk@gmail.com
Study Contact Backup
- Name: Vikram Bhatia, D.M
- Phone Number: 91 9818014864
- Email: vikrambhatiadr@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All consecutive in-patients and out-patients undergoing ERCP .
Description
Inclusion Criteria: • Patients Undergoing ERCP -
Exclusion Criteria: Patients with missing dosimetry data
-
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Estimate the distribution of total radiation dose (median, IQR, 75th percentile) reflected by DAP (Gy·cm²) for ERCP and propose local DRLs.
Time Frame: Day 0
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
- Estimation of Diagnostic reference (DRLs) -(median, IQR, 75th percentile)for ERCP procedures for Ka,r (in mGy) , FT (in min),ED(in mSv).
Time Frame: Day 0
|
Day 0
|
|
- Patient's fluoroscopy time (in min), reference air-kerma (in mGy), and number of acquisitions(n) will be measured
Time Frame: Day 0
|
Day 0
|
|
- Correlation of DAP and Ka,r with ASGE complexity grade, HOUSE grading, Stanford fluoroscopy complexity scores will be done using Spearman rank correlation coeffecient
Time Frame: Day 0
|
Day 0
|
|
- Track proportion of cases exceeding candidate DRLs or published reference values to guide procedure optimization.
Time Frame: Day 0
|
Day 0
|
|
Multivariate regression will be used for correlation of procedure indication, BMI(kg/m²), prior sphincterotomy(yes/no), trainee involvement (yes/no), collimation(yes/no), and image acquisitions with DAP(Gy·cm²) and Ka,r (in mGy)
Time Frame: Day 0
|
Day 0
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Postoperative Complications
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Chronic Disease
- Disease Attributes
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Pancreatic Diseases
- Biliary Tract Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Carcinoma
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Cholelithiasis
- Common Bile Duct Diseases
- Pathological Conditions, Signs and Symptoms
- Cholangitis
- Pancreatitis
- Carcinoma, Hepatocellular
- Pancreatitis, Chronic
- Cholangitis, Sclerosing
- Bile Duct Neoplasms
- Choledocholithiasis
- Pancreatitis, Acute Necrotizing
- Postcholecystectomy Syndrome
Other Study ID Numbers
- ILBS-ERCP-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.